The US site will significantly expand the Company's current production capacity. Once completed, it is expected to allow uniQure to capitalize on its modular manufacturing platform and leverage its process leadership in commercial grade AAV manufacturing. With two validated manufacturing sites on stream, the Company will be able to ensure it can supply commercial grade material for its pipeline of products as they advance into pivotal studies and will be positioned as the partner of choice for the manufacturing, development and commercialization of AAV-based gene therapies.
In connection with uniQure's US expansion, the Company has appointed
In addition, uniQure raised
"The construction of this facility represents our commitment to establishing a global, fully integrated gene therapy company as we continue to build on our leadership position in the field of AAV-based gene therapy products," said JÖrn Aldag, CEO of uniQure.
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. www.uniqure.com.
This press release contains forward-looking statements based on uniQure's current expectations. These forward-looking statements include statements regarding the completion of the build-out of our new manufacturing facility, receipt of regulatory approval of our manufacturing facility, and the development of additional gene therapies. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties regarding further regulatory requirements, the success of further clinical trials, and competitive pressures. uniQure assumes no responsibility to update such forward-looking statements.
Press release (PDF): http://hugin.info/157414/R/1719581/572296.pdf
Jorn AldagCEO uniQure T: +31 20 566 8014 email@example.com Media inquiries MacDougall Biomedical Communications Doug MacDougall(US) +1 781 235 3060 firstname.lastname@example.org Gretchen Schweitzer( Europe) +49 172 861 8540 email@example.com